Integrin-mediated transcriptional activation of inhibitor of apoptosis proteins protects smooth muscle cells against apoptosis induced by degraded collagen.
Apoptosis of smooth muscle cells (SMC) and degradation of the extracellular matrix (ECM) have both been implicated in atherosclerotic plaque rupture. We have previously reported that degraded type I collagen fragments induce a rapid but transient apoptotic burst initiated by calpains in SMC. The aim of the current study was to identify the pathway responsible for consecutive SMC survival. We show that exposure of SMC to collagen fragments resulted in a sustained activation of nuclear factor (NF)-kappaB via phosphorylation and degradation of IkappaBalpha. Its prevention through retroviral expression of superrepressor IkappaBalpha or proteasome inhibition potently induced apoptosis. In the presence of blocking antibodies to alpha(v)beta(3) integrin and RGD peptides, collagen fragments no longer activated NF-kappaB and apoptosis was enhanced. The mechanism by which NF-kappaB was protecting SMC against collagen fragment-induced apoptosis was a transcriptional activation of several endogenous caspase inhibitors of the inhibitor of apoptosis protein (IAP) family as: (1) the expression of xIAP, c-IAP2, and survivin was potently induced by collagen fragments; (2) IAP expression was abrogated by superrepressor IkappaBalpha; and (3) knockdown of each of the 3 IAPs by small interfering RNA (siRNA) resulted in enhanced apoptosis after collagen fragment treatment. Our data suggest that SMC exposed to degraded collagen are protected against apoptosis by a mechanism involving alpha(v)beta(3)-dependent NF-kappaB activation with consequent activation of IAPs. This may constitute a novel antiapoptotic pathway ensuring SMC survival in settings of enhanced ECM degradation such as cell migration, vascular remodeling, and atherosclerotic plaque rupture.
von Wnuck Lipinski
Karin
K
Institute of Pathophysiology, Center of Internal Medicine, University Hospital, Essen, Germany.
Keul
Petra
P
Ferri
Nicola
N
Lucke
Susann
S
Heusch
Gerd
G
Fischer
Jens W
JW
Levkau
Bodo
B
D017209:Apoptosis / Q000502:physiology*; D002478:Cells, Cultured; D003094:Collagen / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D006801:Humans; D020672:I-kappa B Proteins / Q000494:pharmacology; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics*; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors / Q000502:physiology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000502:physiology*; D016328:NF-kappa B / Q000187:drug effects / Q000502:physiology; D010446:Peptide Fragments / Q000494:pharmacology; D061988:Proteasome Inhibitors; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000494:pharmacology; D015533:Transcriptional Activation / Q000502:physiology*
D020672:I-kappa B Proteins; D051034:Inhibitor of Apoptosis Proteins; D039302:Integrin alphaVbeta3; D016328:NF-kappa B; D010446:Peptide Fragments; D061988:Proteasome Inhibitors; D011500:Protein Synthesis Inhibitors; D034741:RNA, Small Interfering; D003094:Collagen; D003513:Cycloheximide